Rinat K. Raupov

Saint Petersburg, SPE 197136, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.

Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 15, 2025

The Features of Children with Juvenile Idiopathic Arthritis with Cervical Spine Involvement in the Data from a Retrospective Study Cohort.

The Features of Children with Juvenile Idiopathic Arthritis with Cervical Spine Involvement in the Data from a Retrospective Study Cohort.

Journal: Journal of functional morphology and kinesiology

Published: December 15, 2024

Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study.

Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study.

Journal: World journal of nephrology

Published: June 25, 2024

Forty-one Cytokine Profile and Interferon-I Score in Juvenile Dermatomyositis: A Case Series Study.

Forty-one Cytokine Profile and Interferon-I Score in Juvenile Dermatomyositis: A Case Series Study.

Journal: Recent advances in inflammation & allergy drug discovery

Published: April 12, 2024

IFN-I Score and Rare Genetic Variants in Children with Systemic Lupus Erythematosus.

IFN-I Score and Rare Genetic Variants in Children with Systemic Lupus Erythematosus.

Journal: Biomedicines

Published: April 01, 2024

BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study.

BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study.

Journal: World journal of clinical pediatrics

Published: October 19, 2023

Juvenile Dermatomyositis and Infantile Cerebral Palsy: Aicardi-Gouteres Syndrome, Type 5, with a Novel Mutation in SAMHD1-A Case Report.

Juvenile Dermatomyositis and Infantile Cerebral Palsy: Aicardi-Gouteres Syndrome, Type 5, with a Novel Mutation in SAMHD1-A Case Report.

Journal: Biomedicines

Published: May 15, 2023

Interferon type I signature associated with skin disease in juvenile dermatomyositis.

Interferon type I signature associated with skin disease in juvenile dermatomyositis.

Journal: Frontiers in medicine

Published: April 30, 2023

IFIH1 and DDX58 gene variants in pediatric rheumatic diseases.

IFIH1 and DDX58 gene variants in pediatric rheumatic diseases.

Journal: World journal of clinical pediatrics

Published: December 30, 2022

Simultaneous Onset of Pediatric Systemic Lupus Erythematosus in Twin Brothers: Case Report.

Simultaneous Onset of Pediatric Systemic Lupus Erythematosus in Twin Brothers: Case Report.

Journal: Frontiers in pediatrics

Published: April 26, 2022

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis.

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis.

Journal: Frontiers in pediatrics

Published: March 12, 2022

The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience.

The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience.

Journal: Frontiers in pediatrics

Published: November 23, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026